Trial Profile
A retrospective study to evaluate the efficacy of adalimumab and infliximab as a monotherapy or in combination with an immunomodulator for the treatment of Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine (Primary) ; Infliximab (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 02 Nov 2016 New trial record
- 26 Sep 2016 Results published in the Alimentary Pharmacology and Therapeutics